Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
Debu Tripathy(The University of Texas MD Anderson Cancer Center), Cláudia Vieira, Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Craig Underhill(AstraZeneca (United Kingdom)), Georgeta Fried(Roche (Switzerland)), Carey K. Anders(Duke University), Andrew D. Seidman(Memorial Sloan Kettering Cancer Center), Hugues Bourgeois(Barwon Health), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Orditura(University of Campania "Luigi Vanvitelli"), Michael P. Thirlwell(McGill University Health Centre), Philippe Barthélémy(Centre National de la Recherche Scientifique), François P. Duhoux(Cliniques Universitaires Saint-Luc), Marie-Pascale Graas, Ute Hoch(University of Arizona), Margarita Tokar, Maureen Trudeau(Trillium Health Centre), Pauline Wimberger(University Hospital Carl Gustav Carus), Philip R. Clingan(Wollongong Hospital), Javier Cortés(Villa Maria Hospital), Francesco Cognetti(Apple (Israel)), Marco Colleoni(European Institute of Oncology), Ines Deleu, Véronique Dièras(Institut Curie), Yining Du(AbbVie (United States)), Luca Gianni(Fondazione Michelangelo), Thierry Velu(Radboud University Nijmegen), Sara M. Tolaney(Harvard University), Mary Tagliaferri(Nektar Therapeutics (United States)), Nuhad K. Ibrahim(The University of Texas MD Anderson Cancer Center), Chris Twelves(University of Leeds), Ido Wolf(Tel Aviv University), Tanja Fehm(Düsseldorf University Hospital), Elgene Lim(St Vincent's Hospital Sydney), Alison L. Hannah(CytomX Therapeutics (United States)), Hope S. Rugo(City of Hope), Konstantinos Papadimitriou, Sue Currie(St. Paul's Hospital), Volkmar Müller(Universität Hamburg), Daphne Tsoi, Carmelo Bengala, Delphine Loirat(Institut Curie), Jean-Luc Canon, Mireille Mousseau, Marleen Borms, Jean‐Christophe Théry, Arlene Chan(Curtin University), Susan Chua, Miruna Timar David
Cited by 24
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k